Piper Sandler Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem maintains an Overweight rating on Amneal Pharmaceuticals (NYSE:AMRX) and raises the price target from $3 to $5.
August 07, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler maintains an Overweight rating on Amneal Pharmaceuticals and raises the price target from $3 to $5.
The news is directly related to Amneal Pharmaceuticals. Piper Sandler's Overweight rating and increased price target suggest a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100